Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
|Articles|April 1, 2010
To Uncover Practice Problems, Go Undercover
Consider having a friend or family member evaluate your practice as a “mystery shopper.”
Advertisement
Consider having a friend or family member evaluate your practice as a "mystery shopper." He or she can provide valuable feedback about your phone system and front office staff; the contents, layout, and "feel" of the waiting room; and other aspects of your practice from a patient's perspective.
--
Benjamin Barankin, MD
Toronto
Advertisement
Related to this article
The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.
Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.
TMS 2026: Menopause was coded in just 7.8% of midlife outpatient visits. Arina Chesnokova, MD, MPH, discusses diagnosis gaps, prescribing risks, and solutions for primary care.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Clears 15-Minute Blood Test to Help Distinguish Bacterial From Viral Infections
2
4 FDA Decisions for Primary Care to Know from October 2026
3
Evolocumab Tied to 20% Lower Risk of Myocardial Infarction vs Ezetimibe in Real-World Study
4
The Future of HIV PrEP and One Step to Take Tomorrow
5